Symeres acquires Woburn’s Organix, Adds Strategic Foothold in US

Leading European drug discovery CRO/CDMO Symeres is set to acquire Woburn-based Organix, a provider of high-quality organic chemistry services focused on lipids. The Organix acquisition adds a high-quality presence in the US market, where Symeres generates nearly 50% of its revenues, and broadens Symeres’ drug discovery offering into the fast-growing lipids market, addressing mRNA therapeutics and vaccines. Organix’s impressive client list includes some of the world’s leading biopharma companies, including many based in the Boston biopharma community.

Headquartered in the Netherlands, Symeres is one of the largest European small molecule CRO & CDMOs, providing R&D services from preclinical drug discovery to Phase I and II clinical stage drug development and manufacturing, to major pharmaceutical and biotechnology companies worldwide. The company employs over 500 people, many of whom are PhD scientists, operating in the Netherlands, the Czech Republic, and Nordics, along with an existing business development office in the Boston area. The company offers best-in-class solutions for drug discovery and drug development for small molecules and beyond. Their services span from preclinical hit finding all the way to the delivery of early clinical phase drug substance API. (Source: Symeres Website, 26 April, 2022)